Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives.
The present article reviews the clinical trials that have been performed in recurrent medullary thyroid carcinoma patients with the Affinity Enhancement System. This technique uses bispecific antibodies to target radiolabelled bivalent haptens to tumour cells. Its sensitivity in the detection of known tumour sites is high (90%) and this technique also achieves good sensitivity (61%) in the detection of occult disease as revealed by abnormal thyrocalcitonin blood levels. Due to its high targeting capacity, this technique is now considered for use as a therapeutic agent in medullary thyroid carcinoma patients.
Rouvier
E
E
Imaging and Therapeutics Department, Immunotech SA, Marseille, France.
Gautherot
E
E
Meyer
P
P
Barbet
J
J
D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D018033:Antibodies, Bispecific / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000601:surgery; D006241:Haptens / Q000627:therapeutic use; D006801:Humans; D011829:Radiation Dosage; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000601:surgery
D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D006241:Haptens